Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort studyDavid van Duin, Robert A. Bonomo, Bettina C. Fries et al.|The Lancet Infectious Diseases|2020Cited by 328
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Maha Assi et al.|Drugs|2022Cited by 273
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Iván O. Rosas, Min Bao, Norbert Bräu et al.|EClinicalMedicine|2022Cited by 37
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Maha Assi et al.|Drugs|2022Cited by 6
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19Stephen J. Balevic, Oscar Carbajal, Daniel K. Benjamin et al.|JAMA Network Open|2024Cited by 6